<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00425074</url>
  </required_header>
  <id_info>
    <org_study_id>TROM-EC-ECC-FIb</org_study_id>
    <nct_id>NCT00425074</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic-pharmacokinetic Trial, of Slow Release ASA, in the Platelet Functionalism.</brief_title>
  <official_title>Pharmacodynamic- Pharmacokinetic Trial, Comparative Double Blind, of the Chronic Administration of 150 mg of Slow Release ASA Versus 150 mg of Normal Release ASA, in the Platelet Functionalism.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rottapharm Spain</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rottapharm Spain</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the platelet antiaggregant effect that a chronic
      treatment with ASA (150 mg) produces,comparing this effect between two formulations of ASA:
      normal and the one of sustained release, in patients with stable coronary disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A large clinical trials have established the efficacy of the antiaggregant products in
      patients with ischemic cardiopathy, stroke and intermittent claudication.

      Without doubt, the acetylsalicylic acid (ASA) is the most used antiaggregant product,
      nevertheless, and spite of being centenarian, it last some questions pending regarding the
      most appropriate dose, mechanism of action implicated, the association with other drugs, and
      the pharmaceutical form in order to improve the efficacy and the safety of the ASA.

      Some previous studies indicate that the slow release form of ASA has a different behaviour in
      the platelet effect in comparison with plain formulation.

      The aim of this study is to demonstrate the best antiaggregant and safety profile of a low
      dose of a slow release formulation of ASA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of the treatment with ASA (150 mg) produces on the thromboxan/prostacyclin balance and its repercussion in the platelet aggregation,comparing this effect between two formulations</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the principal kinetic parameters of both galenic formulations of ASA.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>SR-ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>slow release acetylsalicylic acid 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>normal release acetylsalicylic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>slow release acetyl salicylic acid</intervention_name>
    <description>150 mg in capsules via oral, during 14 days.</description>
    <arm_group_label>SR-ASA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA</intervention_name>
    <description>normal release acetylsalicylic acid</description>
    <arm_group_label>ASA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR-ASA</intervention_name>
    <description>slow release acetylsalicylic acid 150 mg</description>
    <arm_group_label>SR-ASA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous episodes of myocardial infarction

          -  Previous episodes of instable angina pectoris

          -  Previous coronary revascularization

          -  Significant arterial coronary disease

        Exclusion Criteria:

          -  Patients with other pathologies that requires treatment with other antiaggregants

          -  Patients in treatment with low molecular weight heparin or oral anticoagulant

          -  Patients with antecedents of hypersensibility to ASA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eloy Rueda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosp. Universitario Virgen de la Victoria, Málaga (Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Pedro de la Cruz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departmento de Farmacología y Terapéutica Clínica Facultad de Medicina, Universidad de Málaga</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Antonio González Correa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departamento de Farmacología y Terapéutica Clínica Facultad de Medicna, Universidad de Málaga</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2007</study_first_submitted>
  <study_first_submitted_qc>January 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2007</study_first_posted>
  <last_update_submitted>June 7, 2011</last_update_submitted>
  <last_update_submitted_qc>June 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <keyword>slow release ASA</keyword>
  <keyword>platelet functionalism</keyword>
  <keyword>secondary cardiovascular prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

